ZR-202-CoV / Walvax 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  ZR202a-CoV / Walvax, ZR-202-CoV / Walvax
    Enrollment closed, Trial completion date:  Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults. (clinicaltrials.gov) -  Apr 20, 2023   
    P1/2,  N=60, Active, not recruiting, 
    The magnitudes of immune responses compared favorably with COVID-19 vaccines with reported protective efficacy. Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Aug 2023
  • ||||||||||  ZR-202-CoV / Walvax
    Enrollment closed, Trial completion date, Trial primary completion date:  Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 (clinicaltrials.gov) -  Apr 19, 2023   
    P1/2,  N=84, Active, not recruiting, 
    N=1056 --> 528 | Trial completion date: Oct 2022 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Apr 2022 Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> May 2022
  • ||||||||||  ZR-202-CoV / Walvax
    Enrollment closed, Enrollment change, Trial completion date:  Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 (clinicaltrials.gov) -  Apr 19, 2023   
    P1,  N=72, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2023 | Trial primary completion date: Sep 2022 --> May 2022 Recruiting --> Active, not recruiting | N=144 --> 72 | Trial completion date: Oct 2022 --> Jun 2023
  • ||||||||||  CoronaVac / Sinovac, Bio Farma Indonesia
    P2 data, Journal:  Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. (Pubmed Central) -  Oct 4, 2022   
    More effective vaccine candidates against variants of concern as a booster dose are needed in people primed with two-dose inactivated COVID-19 vaccines...250 eligible volunteers, who had received a prime two-dose CoronaVac (3 to 5 weeks apart) vaccination 100-270 days before, were randomly assigned in a 1:1:1:1:1 ratio to receive a third dose of RQ3013 (30 μg mRNA per 0.15 mL), ChAdTS-S (5×10 viral particles per 0.5 mL), ZR202-CoV (25 μg prefusion-stabilized Spike ectodomain trimer per 0.5 mL), CoronaVac (3 μg inactivated CN02 strain of SARS-CoV-2 per 0.5 mL) or placebo (0.5 mL of 0.9% sodium chloride solution) via intramuscular injection into the upper arm at a single clinical site in Kunming, China...Although all study vaccines boosted neutralising antibodies with no safety concerns, RQ3013 showed much stronger cross-neutralisation and cellular responses, adding more effective vaccine candidates against the omicron variant. Yunnan Provincial Science and Technology Department China (202102AA100051 and 202003AC100010), the Double First-class University funding to Yunnan University, National Natural Science Foundation of China (81960116, 82060368 and 82170711), Yunnan Natural Science Foundation (202001AT070085), High-level Health Technical Personnel Project of Yunnan Province (H-2018102) and Spring City Plan: The High-level Talent Promotion and Training Project of Kunming.
  • ||||||||||  ZR-202-CoV / Walvax
    Enrollment closed:  Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 (clinicaltrials.gov) -  Sep 1, 2022   
    P2,  N=1056, Active, not recruiting, 
    Yunnan Provincial Science and Technology Department China (202102AA100051 and 202003AC100010), the Double First-class University funding to Yunnan University, National Natural Science Foundation of China (81960116, 82060368 and 82170711), Yunnan Natural Science Foundation (202001AT070085), High-level Health Technical Personnel Project of Yunnan Province (H-2018102) and Spring City Plan: The High-level Talent Promotion and Training Project of Kunming. Recruiting --> Active, not recruiting